R&D Trends

Shire, Foundation Fighting Blindness ink research agreement for rare pediatric eye disease

Monday, May 4, 2015 01:01 PM

Shire and the Foundation Fighting Blindness, a national nonprofit organization focused on the entire spectrum of retinal diseases, have formed a new agreement to further research for a novel treatment for autosomal dominant retinitis pigmentosa (adRP), a rare genetic disease that usually first occurs in late childhood or adolescence and is followed by the progressive loss of peripheral vision. There currently are no approved treatment options for adRP.

More... »


NIH awards $17.9 million for blinding diseases research

Friday, May 1, 2015 12:58 PM

The National Eye Institute (NEI) has awarded five projects funds to develop new technology to noninvasively image cells of the eye as part of its Audacious Goals Initiative. NEI has committed $3.8 million to the projects in 2015 and up to $17.9 million over the next five years, pending the availability of funds. NEI is part of the National Institutes of Health.

More... »


AstraZeneca, Celgene collaborate on serious blood cancers

Friday, May 1, 2015 12:51 PM

AstraZeneca and MedImmune, AZ’s global biologics R&D arm, have entered into an exclusive collaboration agreement with Celgene for the development and commercialization of MEDI4736 across a range of blood cancers including non-Hodgkin's lymphoma, myelodysplastic syndromes and multiple myeloma.

More... »

Calico, Buck Institute ink agreement to research the biology of aging

Thursday, April 30, 2015 12:02 PM

Calico, a Google-founded R&D company focused on aging research and therapeutics, and the Buck Institute for Research on Aging, based in California, have partnered to support research into longevity and age-related diseases. Financial terms have not been disclosed.

More... »

Report: Pipeline advancements, asset acquisitions fueled biotech R&D spend in 2014

Wednesday, April 29, 2015 12:17 PM

The combined spend on R&D for the peer group of 35 mid-cap biotech companies increased by nearly $2 billion to reach a total of $9.7 billion in 2014, primarily thanks to top spenders Regeneron and Vertex, according to research and consulting firm GlobalData.

More... »

OncoGenex regains rights to custirsen from Teva

Wednesday, April 29, 2015 12:15 PM

OncoGenex Pharmaceuticals has announced its wholly owned subsidiary, OncoGenex Technologies, executed a termination agreement with Teva under which OncoGenex will regain rights to custirsen, an investigational compound currently in phase III clinical development as a treatment for prostate and lung cancers. This transfer of rights occurs in connection with the termination of the 2009 collaboration agreement between OncoGenex and Teva.

More... »

Resverlogix, Shenzhen Hepalink Pharma ink $450M deal

Wednesday, April 29, 2015 12:12 PM

Resverlogix, a clinical stage cardiovascular company based in Canada, and China-based Shenzhen Hepalink Pharmaceutical have formed a combination licensing and equity arrangement for RVX-208 in China, Hong Kong, Taiwan and Macau. The completion of the transaction remains subject to execution of a definitive stock purchase agreement and license agreement.

More... »

uBiome launches Clinical Lab

Wednesday, April 29, 2015 12:10 PM

San Francisco-based uBiome has launched a CLIA-regulated clinical laboratory to provide clinical tests based on its unique microbial assays.

More... »

Accenture, Oracle expand Life Sciences Cloud for R&D

Friday, April 24, 2015 01:14 PM

Accenture, a global management consulting, technology services and outsourcing company, has expanded the Accenture Life Sciences Cloud for R&D, powered by Oracle, with the addition of enhanced clinical data management capabilities. This enables life sciences companies to generate high-quality, reliable and statistically sound data from clinical trials to reduce the time, effort and cost needed to take drugs from development to market.

More... »

Curadev, Roche ink research cancer immunotherapeutic collaboration

Wednesday, April 22, 2015 12:13 PM

Curadev Pharma, headquartered in New Delhi, India, has entered into a research collaboration and exclusive license agreement with Roche for the development and commercialization of IDO1 and TDO inhibitors. The agreement covers the development of the lead preclinical immune tolerance inhibitor and a research collaboration with Roche's research and early development organization to further explore the IDO and TDO pathways.

More... »

CWWeekly

June 29

FDA and PatientsLikeMe collaborate to test social media adverse event reporting

Boston-area teaching hospitals launch web portal to attract life science companies

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

July

Integrated research partnerships build momentum
Research function provides infrastructure, leverages large pool of health systems' patients and data

'Right to Try' laws challenge clinical trial process
20 states pass, 20 more pending allowing access to study drugs without FDA and IRB approval

Already a subscriber?
Log in to your digital subscription.

Purchase the July issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

June

TransCelerate Biopharma turns three
High-profile consortium has made inroads fixing wasteful practices, but it still has more work ahead

Pharma industry improves its tarnished reputation
Delivering innovation, social responsibility will help rebuild trust

Already a subscriber?
Log in to your digital subscription.

Purchase the June issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs